[Hyperthemia enhances activated lymphocytes and molecular target therapy].
We already informed that a combination therapy of hyperthermia and activated lymphocytes therapy reduced the tumor growth and lung metastasis synergistically in mice model. In this study we treated mice inoculated LLC tumors with hyperthermia or molecular target drugs (erlotinib 25 mg/kg/day and sorafenib 10 mg/kg/day). Both of hyperthermia and molecular target therapy reduced not only tumor growth but also lung metastasis. And a combination therapy of hyperthermia and molecular target therapy reduced more of the tumor growth and lung metastasis synergistically. The expression of HER2 and VEGFR was reduced by hyperthermia and molecular target drugs. Apoptosis was enhanced by hyperthermia and molecular target drugs synergistically.
Osaka Cancer Immuno-Chemotherapy Center.
Tsutomu
T
Takeda
Takeo
T
Hasegawa
Kenki
K
Miyazawa
Kana
K
Yoshida
Takashi
T
Takeda
Hiroko
H
Takeda
Tohru
T
Takahashi
Itsuo
I
Yamamoto
Shohgo
S
Kobayashi
D000818:Animals; D017209:Apoptosis; D018450:Disease Progression; D006979:Hyperthermia, Induced; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*